Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) FCF Margin (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed FCF Margin for 13 consecutive years, with 24.29% as the latest value for Q4 2025.

  • Quarterly FCF Margin fell 1847.0% to 24.29% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 275.53% through Dec 2025, up 29396.0% year-over-year, with the annual reading at 221.93% for FY2025, 24037.0% up from the prior year.
  • FCF Margin for Q4 2025 was 24.29% at Theravance Biopharma, up from 32.56% in the prior quarter.
  • The five-year high for FCF Margin was 794.33% in Q2 2025, with the low at 1077.36% in Q1 2022.
  • Average FCF Margin over 5 years is 100.41%, with a median of 31.89% recorded in 2024.
  • The sharpest move saw FCF Margin skyrocketed 323457bps in 2021, then tumbled -57493bps in 2022.
  • Over 5 years, FCF Margin stood at 305.73% in 2021, then skyrocketed by 235bps to 411.26% in 2022, then plummeted by -102bps to 8.72% in 2023, then skyrocketed by 33bps to 5.82% in 2024, then tumbled by -317bps to 24.29% in 2025.
  • According to Business Quant data, FCF Margin over the past three periods came in at 24.29%, 32.56%, and 794.33% for Q4 2025, Q3 2025, and Q2 2025 respectively.